Fig. 3From: How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big dataResults of the regression analysis of the monthly proportion of lenvatinib and sorafenib usageBack to article page